BR112023002116A2 - Proteínas que se ligam a nkg2d, cd16 e egfr - Google Patents

Proteínas que se ligam a nkg2d, cd16 e egfr

Info

Publication number
BR112023002116A2
BR112023002116A2 BR112023002116A BR112023002116A BR112023002116A2 BR 112023002116 A2 BR112023002116 A2 BR 112023002116A2 BR 112023002116 A BR112023002116 A BR 112023002116A BR 112023002116 A BR112023002116 A BR 112023002116A BR 112023002116 A2 BR112023002116 A2 BR 112023002116A2
Authority
BR
Brazil
Prior art keywords
egfr
proteins
nkg2d
binding nkg2d
bind
Prior art date
Application number
BR112023002116A
Other languages
English (en)
Inventor
F Cheung Ann
V Drabic Stacey
Grinberg Asya
Sean Juo Zong
Liharska Katia
Ryan Morgan Christopher
Wagtmann Nicolai
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of BR112023002116A2 publication Critical patent/BR112023002116A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEÍNAS QUE SE LIGAM A NKG2D, CD16 E EGFR. São descritas neste documento proteínas de ligação multiespecíficas que se ligam ao receptor NKG2D, CD16 e EGFR, bem como composições farmacêuticas e métodos terapêuticos úteis para o tratamento do câncer.
BR112023002116A 2020-08-05 2021-08-05 Proteínas que se ligam a nkg2d, cd16 e egfr BR112023002116A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061510P 2020-08-05 2020-08-05
PCT/US2021/044737 WO2022031965A1 (en) 2020-08-05 2021-08-05 Proteins binding nkg2d, cd16 and egfr

Publications (1)

Publication Number Publication Date
BR112023002116A2 true BR112023002116A2 (pt) 2023-04-25

Family

ID=77519840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002116A BR112023002116A2 (pt) 2020-08-05 2021-08-05 Proteínas que se ligam a nkg2d, cd16 e egfr

Country Status (11)

Country Link
US (1) US20230257467A1 (pt)
EP (1) EP4192872A1 (pt)
JP (1) JP2023536567A (pt)
KR (1) KR20230042519A (pt)
CN (1) CN117730096A (pt)
AU (1) AU2021320311A1 (pt)
BR (1) BR112023002116A2 (pt)
CA (1) CA3188215A1 (pt)
IL (1) IL300249A (pt)
MX (1) MX2023001555A (pt)
WO (1) WO2022031965A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
WO2024035662A2 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Proteins binding nkg2d, cd16, and ceacam5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
NZ726514A (en) * 2014-05-29 2019-01-25 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.

Also Published As

Publication number Publication date
AU2021320311A1 (en) 2023-03-02
IL300249A (en) 2023-03-01
CA3188215A1 (en) 2022-02-10
CN117730096A (zh) 2024-03-19
EP4192872A1 (en) 2023-06-14
MX2023001555A (es) 2023-03-08
US20230257467A1 (en) 2023-08-17
KR20230042519A (ko) 2023-03-28
WO2022031965A1 (en) 2022-02-10
JP2023536567A (ja) 2023-08-28

Similar Documents

Publication Publication Date Title
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
WO2019126514A3 (en) Antibodies to lilrb2
BR112017001513A2 (pt) molécula de ligação biespecífica, polinucleotídeo, vetor, célula ex vivo, método de produção de uma molécula de ligação biespecífica, mistura de polinucleotídeos, composição farmacêutica, método de tratamento de um câncer, método de preparação de uma célula
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
CR20120454A (es) Proteínas terapéuticas de unión a dll4
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.